anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Streptococcus agalactiae (or group B Streptococcus, GBS) is a leading cause of neonatal sepsis and meningitis globally. To sense and respond to variations in its environment, GBS possesses multiple two-component regulatory systems (TCSs), such as LytSR. Here, we aimed to investigate the role of LytSR in GBS pathogenicity. We generated an isogenic lytS knockout mutant in a clinical GBS isolate and used a combination of phenotypic in vitro assays and in vivo murine models to investigate the contribution of lytS to the colonization and invasive properties of GBS. Deletion of the lytS gene in the GBS chromosome resulted in significantly higher survival rates in mice during sepsis, accompanied by reduced bacterial loads in blood, lung, spleen, kidney, and brain tissues compared to infection with the wild-type strain. In a mouse model of GBS vaginal colonization, we also observed that the lytS knockout mutant was cleared more readily from the vaginal tract compared to its wild-type counterpart. Interestingly, lower levels of proinflammatory cytokines were found in the serum of mice infected with the lytS mutant. Our results demonstrate that the LytSR TCS plays a key role in GBS tissue invasion and pathogenesis, and persistence of mucosal colonization.IMPORTANCEStreptococcus agalactiae (group B Streptococcus, or GBS) is a common commensal of the female urogenital tract and one of WHO's priority pathogens. The bacterium has evolved mechanisms to adapt and survive in its host, many of which are regulated via two-component signal transduction systems (TCSs); however, the exact contributions of TCSs toward GBS pathogenicity remain largely obscure. We have constructed a TCS lytS-deficient mutant in a CC-17 hypervirulent GBS clinical isolate. Using murine models, we showed that LytSR regulatory system is essential for vaginal colonization via promoting biofilm production. We also observed that lytS deficiency led to significantly attenuated virulence properties and lower levels of proinflammatory cytokines in blood. Our findings are of significant importance in that they unveil a previously unreported role for LytSR in GBS and pave the way toward a better understanding of its ability to transition from an innocuous commensal to a deadly pathogen.
We describe a strategy for designing and implementing protein-fragment complementation assays (PCAs) to detect biomolecular interactions in vivo and in vitro. The design, implementation and broad applications of this strategy are illustrated with a large number of enzymes with particular detail provided for the example of murine dihydrofolate reductase (DHFR). Fusion peptides consisting of N- and C-terminal fragments of murine DHFR fused to GCN4 leucine zipper sequences were coexpressed in  Escherichia coli  grown in minimal medium, where the endogenous DHFR activity was inhibited with trimethoprim. Coexpression of the complementary fusion products restored colony formation. Survival only occurred when both DHFR fragments were present and contained leucine-zipper forming sequences, demonstrating that reconstitution of enzyme activity requires assistance of leucine zipper formation. DHFR fragment-interface point mutants of increasing severity (Ile to Val, Ala and Gly) resulted in a sequential increase in  E. coli  doubling times illustrating the successful DHFR fragment reassembly rather than non-specific interactions between fragments. This assay could be used to study equilibrium and kinetic aspects of molecular interactions including protein-protein, protein-DNA, protein-RNA, protein-carbohydrate and protein-small molecule interactions, for screening cDNA libraries for binding of a target protein with unknown proteins or libraries of small organic molecules for biological activity. The selection and design criteria applied here is developed for numerous examples of clonal selection, colorometric, fluorometric and other assays based on enzymes whose products can be measured. The development of such assay systems is shown to be simple, and provides for a diverse set of protein fragment complementation applications.
NEW MATERIAL:A compound shown by the formula I (one of R<1>, R<2>, and R<3> is H and the other two are hydroxyl groups). EXAMPLE:1,5-Anhydro-3-deoxy-D-ribo-hexitol. USE:Suppressing activity of glucose acceptive neuron, useful for preventing and remedying unpreferable symptoms caused by facts related to the use of glucose. PREPARATION:A compound shown by the formula II (X is halogen; Y is acyl) is reacted with a metal hydride complex compound such as lithium aluminum hydride, etc. in an inert organic solvent such as THF, etc. at 0-50 deg.C for 1- 3hr, to give a compound shown by the formula I .
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for obtaining internet search data, the search data indicating internet searches performed by a population of users. Obtaining location data associated with each user in the population where the location data represents one or more geographic locations of each user over a period of time. Identifying a subset of the population who are likely carrying a contagion based on the search data. Determining an exposure level of a user to the contagion based on a correlation of a first location data associated with the user with a second location data associated with one or more users in the subset of the population who are likely carrying the contagion. Determining whether the user is likely to be or become ill based on the exposure level. Providing a notification indicating that the user has been exposed to the contagion.
Seven cases of primary lung tumors characterized histologically by clear cell morphology and a distinctive FGFR3::TACC3 gene rearrangement are described. The tumors arose in 4 women and 3 men, aged 47 to 81 years (mean=68). They occurred in peripheral locations, predominantly subpleural, and ranged in size from 1.4 to 6.5 cm (mean=4.1 cm). All tumors showed a solid growth pattern with abundant central areas of necrosis and marked nuclear pleomorphism. The tumors demonstrated clear cell histology, with large cohesive tumor cells displaying atypical nuclei and abundant clear cytoplasm. Immunohistochemical stains identified a squamous phenotype in 5 cases and an adenocarcinoma phenotype in 2 cases. One case was a squamous cell carcinoma with focal glandular component, and one of the squamous cell carcinomas showed focal sarcomatoid changes. Next generation sequencing identified FGFR3::TACC3 gene rearrangements in all 7 cases. One case demonstrated a concurrent activating FGFR3 mutation and a second case demonstrated concurrent FGFR3 amplification. Two cases harbored a concurrent KRAS G12D mutation. One case harbored both KRAS and EGFR mutations, and 1 case had a concurrent TP53 mutation. Non-small cell lung carcinoma harboring FGFR3::TACC3 gene rearrangements is extremely rare, and this rearrangement may potentially be enriched in tumors that demonstrate clear cell histology. Identification of FGFR3::TACC3 in patients with lung carcinomas with clear cell features may be of importance as they could potentially be candidates for therapy with tyrosine kinase inhibitors.
The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic moieties adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic. moiety an adjacent positively charged moiety. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.
The present invention discloses a spraying agent for treating rhinitis, which is composed of the ingredients in the following weight parts of 5 to 20 parts of dahurian angelica, 10 to 60 parts of dried alum, 10 to 40 parts of dragon blood, 5 to 20 parts of borneol, 5 to 30 parts of frankincense, 5 to 20 parts of myrrh, 5 to 20 parts of catechu, 1 to 15 parts of cinnabar, 5 to 30 parts of gall, and 1 to 5 parts of musk. The present invention has the following advantages of external administration, portability, powder-shaped agent, convenient and sanitary administration, rapid curing time, shortened treating course, difficult relapse, patient's pain alleviation and patients' economical burden reduction, and no medicine flows into the oral cavity in the administration. After clinic use and tracking visits, more than one thousand of patients suffered from various kinds of rhinitis are cured, wherein the patients have hypertrophic rhinits, allergic rhinitis, atrophic rhinitis, etc. Compared with various existing treating methods for treating various kinds of rhinitis, the present invention has the advantages of obvious effect and difficult relapse, which is proved by clinical practices. The nasal partial powder administration is used, the duration time of the medical effect is long, systemic side effects are few, no antibiotic exists, and the human body's immunity is not influenced. The present invention develops a new way of using the traditional Chinese medicine for treating the rhinitis.
PURPOSE:To provide an excellent antiviral agent containing the antibiotic substance 3780 which is an antitumor and antibacterial agent separated from Streptomyces sp. 3780 strain, as an active component. CONSTITUTION:The objective antiviral agent contains the antibiotic substance 3780 of formula I as an active component. The compound of formula I is guanine-7-N-oxide having a molecular weight of 167 (by mass-spectrum) and separated from the cultured product of Streptomyces sp. 3780 strain (FERM P-7171). The compound exhibits excellent antiviral activity to infectious hematopoietic necrosis virus by cell culture test and the activity is increased synergistically by the combined use with neplanocin A of formula II. The weight ratio of the compound of formula I to formula II is preferably 1:(1-5).
The invention belongs to the technical field of traditional Chinese medicine compounds, and discloses a licorice yin-nourishing soup and application thereof in improving endothelial cell injury caused by SLE. The decoction containing the medicinal serum has effect in promoting proliferation of human umbilical vein endothelial cells. The licorice yin nourishing decoction contains medicine serum to inhibit human umbilical vein endothelial cell apoptosis. The licorice yin nourishing decoction contains medicine serum to reverse inflammatory injury of human umbilical vein endothelial cells caused by SLE serum. The licorice yin nourishing decoction contains medicine serum to reverse inflammatory aging of human umbilical vein endothelial cells caused by SLE serum. A decoction for nourishing yin comprises Glycyrrhrizae radix, ginseng radix, rhizoma Polygonati Odorati, herba Taraxaci, zingiberis rhizoma, fructus Siraitiae Grosvenorii and fructus Jujubae, wherein Glycyrrhrizae radix is used as principal drug, ginseng radix and rhizoma Polygonati Odorati are used as ministerial drugs, herba Taraxaci, zingiberis rhizoma and fructus Siraitiae Grosvenorii are used as adjuvant drugs, and fructus Jujubae is used as messenger drug. The licorice yin nourishing soup GCNY can reduce endothelial cell apoptosis caused by SLE serum, reverse endothelial cell inflammatory injury and inflammatory aging caused by SLE serum, and protect vascular endothelial cells.
The management of chest tubes is probably one of the most critical aspects in patient care in thoracic surgery and defines the required length of postoperative hospital stay in the majority of patients. So far, no generally accepted recommendations exist for postoperative chest tube management to streamline the postoperative stay. Instead, decision making in most thoracic surgery units is based on team preferences and individual training rather than scientific data. Therefore, digital pleural drainage systems represent a useful tool to standardize existing intradepartmental protocols for chest tube management. However, for the development of generally accepted protocol-recommendations, the diverging interdepartmental treatment protocols have to be analyzed and compared for superiority. In this IIT, the effect of different chest tube management protocols on chest tube duration is analyzed in four German Thoracic Surgery units.
There will be a 3 month pre-intervention phase where participants will be placed on a standard post-operative analgesic regimen consisting of an opioid, a NSAID, and acetaminophen. Patients will record their narcotic and non-opioid analgesic usage patterns in the two weeks following outpatient hand surgery.
The invention relates to a fusion protein, in particular to a fusion protein for targeting tumor and application thereof. A fusion protein has an amino acid sequence shown in SEQ ID NO. 2. It contains all amino acid sequences of thymus peptide alpha 1, and the carboxyl end of the thymus peptide alpha 1 is connected with Fc fragment and tumor targeting peptide iRGD sequence. The fusion protein of the invention is a genetically engineered product expressed in escherichia coli, and the purification process comprises induction expression of the protein, affinity chromatography and gel chromatography. The product exhibits a significantly improved half-life in pharmacokinetic studies and has the function of more effectively restoring the immune system. The in vivo antitumor experiment shows that the fusion protein of the invention has enhanced antitumor effect compared with the original T alpha 1, and can effectively inhibit the growth of colon cancer and lung cancer.
The present invention describes a method for producing microparticles useful in the formulation of pharmaceutical compositions. The present invention further describes a method of immunizing a mammal against diseases comprising administering to a mammal an effective amount of antigen containing microparticles. In particular, the present invention describes a method of potentiating an immune response in a mammal comprising administering an effective amount of a pharmaceutical composition to a mammal. The present invention further describes a vaccine comprising a pharmaceutical composition containing said microparticles. An antigen delivery system comprising microparticles containing entrapped antigens is further described by the present invention. A pharmaceutical composition comprising microparticles and a pharmaceutical carrier is also provided.
After completion of Iber-KDd combination therapy, and In the absence of disease progression, participants will then receive up to twelve (12) 28-day cycles of Iberdomide (Iber) monotherapy. Participants will receive Iber monotherapy for up to 12 months or until disease progression. Participants will be followed for up to three (3) years after conclusion of Iber monotherapy. Total study participation is up to five (5) years.
OBJECTIVES: Clinicians are often hesitant to prescribe psychostimulants in bipolar disorder (BD) due to concerns of inducing (hypo)mania, despite limited published evidence on associations between prescribed psychostimulant use and recurrence of mood episodes in BD. The current systematic review and meta-analysis evaluated the emergence of (hypo)manic symptoms in patients with BD receiving prescribed psychostimulants or other pro-cognitive medications in euthymic or depressive states.
METHODS: A systematic search was performed of MEDLINE, Embase, and PsychINFO from inception to April 5, 2023 and search of Clinicaltrials.gov and Clinicaltrialsregister.eu for unpublished data. References of included studies were hand-searched. Randomized trials and prospective longitudinal studies that evaluated psychostimulants and non-stimulant medications recommended for the treatment of ADHD by the Canadian ADHD practice guidelines were included. The review was reported in line with PRISMA guidelines and was preregistered on PROSPERO (CRD42022358588).
RESULTS: After screening 414 unique records, we included 27 studies, of which five reported data that was quantitatively synthesized (n = 1653). The use of psychostimulants in BD was not associated with increased scores on the Young Mania Rating Scale in patients who were in a euthymic or depressed state (SMD IV -0.17; 95% CI, -0.40 to 0.06) compared to placebo. There was a high degree of study-level heterogeneity (I2 = 80%). A qualitative synthesis of studies revealed a limited risk of medication-induced manic symptoms.
CONCLUSIONS: Our review provides preliminary evidence to suggest psychostimulants and non-stimulant ADHD medications have a limited risk of precipitating (hypo)mania symptoms. More extensive studies evaluating the safety and efficacy of these medications are warranted.
This group will be adults with wet AMD undergoing treatment under the "treat and extend" strategy. (The "treat and extend" strategy increases the intervals between treatments as long as the macula remains dry.) They will be followed over the course of 1 year with extra imaging before extending follow-up intervals.
The use of combination hormonal contraceptives (progestin plus estrogen) increases the risk of vascular events, including arterial events (strokes and myocardial infarctions) or deep venous thrombotic events (venous thromboembolism, deep venous thrombosis, retinal vein thrombosis, and pulmonary embolism). NEXPLANON is a progestin-only contraceptive. It is unknown whether this increased risk is applicable to etonogestrel alone. It is recommended, however, that women with risk factors known to increase the risk of venous and arterial thromboembolism be carefully assessed.

There have been postmarketing reports of serious arterial thrombotic and venous thromboembolic events, including cases of pulmonary emboli (some fatal), deep vein thrombosis, myocardial infarction, and strokes, in women using etonogestrel implants. NEXPLANON should be removed in the event of a thrombosis.

Due to the risk of thromboembolism associated with pregnancy and immediately following delivery, NEXPLANON should not be used prior to 21 days postpartum. Women with a history of thromboembolic disorders should be made aware of the possibility of a recurrence.

Evaluate for retinal vein thrombosis immediately if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions.

Consider removal of the NEXPLANON implant in case of long-term immobilization due to surgery or illness.
BACKGROUND: Previous studies have reported that spondylolysis occurs predominantly at the L5 and L4 levels, with defects at higher levels occurring in <5% of cases. However, computed tomography and radiography were the primary imaging modalities in these studies. Current evidence regarding diagnostic imaging for pediatric lumbar spondylolysis suggests that magnetic resonance imaging (MRI) is as accurate as computed tomography in detecting early stress reactions of the pars interarticularis or pedicles without fractures while avoiding radiation exposure. The early detection of spondylolysis results in a higher likelihood of bony union and a decreased likelihood of spondylolisthesis.
HYPOTHESIS: The increased use of MRI may reveal a larger proportion of spondylolysis in patients who experience an injury at a higher spinal level than previously reported.
STUDY DESIGN: Cross-sectional study; Level of evidence, 3.
METHODS: The medical records of 902 pediatric and adolescent athletes (364 female, 538 male) diagnosed with symptomatic pars interarticularis and pedicle stress injuries at 2 academic medical centers between 2016 and 2021 were retrospectively reviewed. All patients had MRI scans taken at the time of diagnosis. Only patients with pars/pedicle edema on MRI were included. Data regarding spondylolysis stage, spinal level of injury, unilateral versus bilateral injury, sport participation, and MRI protocol over the 5-year study period were analyzed.
RESULTS: Male patients presented at older ages than female patients (P < .001). Soccer was the most common sport at symptom onset and the second most common single-sport activity among those who specialized (participating in 1 sport year-round at the exclusion of others), behind gymnastics. The mean symptom duration was 4.0 months. Although most patients (83.5%) had exclusively lower lumbar stress injuries, 9.1% of injuries occurred at or above the L3 level. Over half of the patients had active single-level pars/pedicle fractures on MRI, with a mean symptom duration before presentation in this subgroup of 4.0 months. Even when pars/pedicle stress reactions were excluded from analysis, 7.1% of patients were injured at or above the L3 level.
CONCLUSION: Among male and female athletes aged 8 to 21 years presenting with symptomatic pars interarticularis and pedicle stress injuries evaluated by MRI at the time of initial diagnosis, there was a higher incidence of upper lumbar stress injuries than previously reported.
The present invention discloses Chinese patent medicine for treating atrophic kidney uremia, which is composed of over ten kinds of Chinese herbal medicine, such as anemarrhena, prepared rehmannia root, cornus officinalis, barbary wolfberry fruit, tangkuei tail, radix paeoniae alba from hangzhou of china, moxibustion astragalus, American ginseng, etc. The Chinese patent medicine for treating atrophic kidney uremia is characterized in that the kidney is firstly moistened for treating the atrophic kidney uremia; a nephridial tissue is moistened, permeated and activated by medicine, which enables a nephridial tissue state to generate change with reversibility; further, kidney functions are improved and restored. The Chinese patent medicine for treating atrophic kidney uremia belongs to medicine treating the root cause of the atrophic kidney uremia. By clinical certification, after the Chinese patent medicine for treating atrophic kidney uremia is taken for one course of treatment, the atrophic nephridial tissue is extended to increase, so the kidney functions are improved. The Chinese patent medicine is also used for treating atrophic kidney uremia is also suitable for treating atrophic brain dementia, amyotrophy, myasthenia, atrophic external kidney, atrophic yang, shrinkage of the scrotum, male's sterility, turbid damp undesending obesity, prostate hypertrophy, etc. in clinical.
In this pilot study, we assessed the role of autophagy in Crohn's Disease (CD), particularly in patients with a stenosing phenotype. Through the analysis of biopsied specimens from 36 patients, including 11 controls and 25 CD patients, categorized into inflammatory and stenosing groups, we identified a significant reduction in the autophagosomal marker Lc3b-II in patients with active inflammation and stenosis. This was paralleled by an increase in oxidative stress markers, including sNOX2-dp and H2O2, and a decrease in the antioxidant capacity measured by HBA, suggesting an imbalance in autophagy and oxidative stress mechanisms. Additionally, our findings show a correlation between autophagy markers and oxidative stress levels, indicating that autophagy dysfunction may play a pivotal role in CD and in the progression of a stenosing disease phenotype, by failing to eliminate detrimental molecules and pathogenic bacteria, thereby promoting fibrosis. This study is the first to demonstrate in vivo autophagy inhibition in stenosing CD patients and suggests that stimulating autophagic processes could offer a new avenue for the prevention and treatment of intestinal fibrosis in CD. Our results highlight the importance of exploring the interactions between autophagy, the fibrotic process, and the inflammatory cascade, opening avenues for potential therapeutic interventions in CD management.